Clinical Trial

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Name: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL — clinical trial record (NCT06363994)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-04-09.

Status change: Not Yet Recruiting → Recruiting 2024-12-20

Trial Details

NCT Number	NCT06363994
Lead Sponsor	InnoCare Pharma Inc.
Conditions	Mantle Cell Lymphoma
Enrollment	476 participants
Start Date	2024-05-29
Primary Completion	2031-06-25 (estimated)
Study Completion	2032-06-25 (estimated)
Updated on ClinicalTrials.gov	2024-12-27